nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—migraine—Prednisone—Crohn's disease	0.188	0.508	CpDpCtD
Naproxen—osteoarthritis—Prednisone—Crohn's disease	0.182	0.492	CpDpCtD
Naproxen—PTGS2—Crohn's disease	0.116	0.529	CbGaD
Naproxen—ALB—Crohn's disease	0.103	0.471	CbGaD
Naproxen—PTGS2—Balsalazide—Crohn's disease	0.0653	0.208	CbGbCtD
Naproxen—PTGS1—Balsalazide—Crohn's disease	0.0552	0.176	CbGbCtD
Naproxen—PTGS2—Mesalazine—Crohn's disease	0.0522	0.166	CbGbCtD
Naproxen—PTGS1—Mesalazine—Crohn's disease	0.0441	0.141	CbGbCtD
Naproxen—PTGS2—Sulfasalazine—Crohn's disease	0.0292	0.093	CbGbCtD
Naproxen—SLCO1A2—Prednisone—Crohn's disease	0.0285	0.0907	CbGbCtD
Naproxen—PTGS1—Sulfasalazine—Crohn's disease	0.0246	0.0785	CbGbCtD
Naproxen—ALB—Prednisone—Crohn's disease	0.0147	0.0469	CbGbCtD
Naproxen—Nabumetone—MPO—Crohn's disease	0.000653	0.223	CrCbGaD
Naproxen—Indomethacin—CXCL8—Crohn's disease	0.000315	0.107	CrCbGaD
Naproxen—Ketoprofen—CXCL8—Crohn's disease	0.000252	0.086	CrCbGaD
Naproxen—Ibuprofen—CXCL8—Crohn's disease	0.000248	0.0846	CrCbGaD
Naproxen—Nabumetone—PTGS2—Crohn's disease	0.000245	0.0836	CrCbGaD
Naproxen—Carprofen—PTGS2—Crohn's disease	0.000234	0.0798	CrCbGaD
Naproxen—Acne—Prednisone—Crohn's disease	0.000164	0.00203	CcSEcCtD
Naproxen—Influenza—Mesalazine—Crohn's disease	0.000164	0.00202	CcSEcCtD
Naproxen—Dysphagia—Mesalazine—Crohn's disease	0.000164	0.00202	CcSEcCtD
Naproxen—Asthma—Mesalazine—Crohn's disease	0.000164	0.00202	CcSEcCtD
Naproxen—Anorexia—Mercaptopurine—Crohn's disease	0.000164	0.00202	CcSEcCtD
Naproxen—Eosinophilia—Mesalazine—Crohn's disease	0.000162	0.002	CcSEcCtD
Naproxen—Pneumonia—Azathioprine—Crohn's disease	0.000161	0.00199	CcSEcCtD
Naproxen—Pancreatitis—Mesalazine—Crohn's disease	0.000161	0.00198	CcSEcCtD
Naproxen—Angina pectoris—Mesalazine—Crohn's disease	0.00016	0.00197	CcSEcCtD
Naproxen—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.000159	0.00196	CcSEcCtD
Naproxen—Bronchitis—Mesalazine—Crohn's disease	0.000158	0.00194	CcSEcCtD
Naproxen—Abdominal discomfort—Mesalazine—Crohn's disease	0.000157	0.00194	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.000156	0.00193	CcSEcCtD
Naproxen—Pancytopenia—Mesalazine—Crohn's disease	0.000156	0.00192	CcSEcCtD
Naproxen—Dysuria—Mesalazine—Crohn's disease	0.000153	0.00189	CcSEcCtD
Naproxen—Arthropathy—Prednisone—Crohn's disease	0.000152	0.00187	CcSEcCtD
Naproxen—Hepatobiliary disease—Azathioprine—Crohn's disease	0.000152	0.00187	CcSEcCtD
Naproxen—Pollakiuria—Mesalazine—Crohn's disease	0.000151	0.00187	CcSEcCtD
Naproxen—Agranulocytosis—Azathioprine—Crohn's disease	0.00015	0.00185	CcSEcCtD
Naproxen—Photosensitivity reaction—Mesalazine—Crohn's disease	0.00015	0.00184	CcSEcCtD
Naproxen—Decreased appetite—Mercaptopurine—Crohn's disease	0.000149	0.00184	CcSEcCtD
Naproxen—Weight decreased—Mesalazine—Crohn's disease	0.000148	0.00183	CcSEcCtD
Naproxen—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000148	0.00183	CcSEcCtD
Naproxen—Pneumonia—Mesalazine—Crohn's disease	0.000147	0.00181	CcSEcCtD
Naproxen—Hypercholesterolaemia—Prednisone—Crohn's disease	0.000146	0.0018	CcSEcCtD
Naproxen—Ulcer—Prednisone—Crohn's disease	0.000146	0.0018	CcSEcCtD
Naproxen—Depression—Mesalazine—Crohn's disease	0.000146	0.0018	CcSEcCtD
Naproxen—Cataract—Prednisone—Crohn's disease	0.000145	0.00179	CcSEcCtD
Naproxen—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.000145	0.00179	CcSEcCtD
Naproxen—Haemoglobin—Azathioprine—Crohn's disease	0.000145	0.00178	CcSEcCtD
Naproxen—Suprofen—PTGS2—Crohn's disease	0.000144	0.0493	CrCbGaD
Naproxen—Haemorrhage—Azathioprine—Crohn's disease	0.000144	0.00178	CcSEcCtD
Naproxen—Renal failure—Mesalazine—Crohn's disease	0.000144	0.00177	CcSEcCtD
Naproxen—Neuropathy peripheral—Mesalazine—Crohn's disease	0.000143	0.00177	CcSEcCtD
Naproxen—Jaundice—Mesalazine—Crohn's disease	0.000142	0.00176	CcSEcCtD
Naproxen—Stomatitis—Mesalazine—Crohn's disease	0.000142	0.00176	CcSEcCtD
Naproxen—Urinary tract infection—Mesalazine—Crohn's disease	0.000142	0.00175	CcSEcCtD
Naproxen—Conjunctivitis—Mesalazine—Crohn's disease	0.000142	0.00175	CcSEcCtD
Naproxen—Vasculitis—Prednisone—Crohn's disease	0.000142	0.00175	CcSEcCtD
Naproxen—Sweating—Mesalazine—Crohn's disease	0.00014	0.00173	CcSEcCtD
Naproxen—Haematuria—Mesalazine—Crohn's disease	0.000139	0.00172	CcSEcCtD
Naproxen—Hepatobiliary disease—Mesalazine—Crohn's disease	0.000138	0.0017	CcSEcCtD
Naproxen—Epistaxis—Mesalazine—Crohn's disease	0.000138	0.0017	CcSEcCtD
Naproxen—Sinusitis—Mesalazine—Crohn's disease	0.000137	0.00169	CcSEcCtD
Naproxen—Agranulocytosis—Mesalazine—Crohn's disease	0.000136	0.00168	CcSEcCtD
Naproxen—Erythema multiforme—Azathioprine—Crohn's disease	0.000136	0.00168	CcSEcCtD
Naproxen—Body temperature increased—Mercaptopurine—Crohn's disease	0.000136	0.00167	CcSEcCtD
Naproxen—Skin exfoliation—Prednisone—Crohn's disease	0.000132	0.00163	CcSEcCtD
Naproxen—Haemoglobin—Mesalazine—Crohn's disease	0.000132	0.00163	CcSEcCtD
Naproxen—Rhinitis—Mesalazine—Crohn's disease	0.000131	0.00162	CcSEcCtD
Naproxen—Haemorrhage—Mesalazine—Crohn's disease	0.000131	0.00162	CcSEcCtD
Naproxen—Hepatitis—Mesalazine—Crohn's disease	0.000131	0.00162	CcSEcCtD
Naproxen—Pharyngitis—Mesalazine—Crohn's disease	0.00013	0.00161	CcSEcCtD
Naproxen—Immune system disorder—Azathioprine—Crohn's disease	0.00013	0.0016	CcSEcCtD
Naproxen—Mediastinal disorder—Azathioprine—Crohn's disease	0.00013	0.0016	CcSEcCtD
Naproxen—Urinary tract disorder—Mesalazine—Crohn's disease	0.000129	0.0016	CcSEcCtD
Naproxen—Oedema peripheral—Mesalazine—Crohn's disease	0.000129	0.00159	CcSEcCtD
Naproxen—Chills—Azathioprine—Crohn's disease	0.000129	0.00159	CcSEcCtD
Naproxen—Connective tissue disorder—Mesalazine—Crohn's disease	0.000129	0.00159	CcSEcCtD
Naproxen—Arrhythmia—Azathioprine—Crohn's disease	0.000129	0.00159	CcSEcCtD
Naproxen—Urethral disorder—Mesalazine—Crohn's disease	0.000129	0.00159	CcSEcCtD
Naproxen—Alopecia—Azathioprine—Crohn's disease	0.000127	0.00157	CcSEcCtD
Naproxen—Hypersensitivity—Mercaptopurine—Crohn's disease	0.000126	0.00156	CcSEcCtD
Naproxen—Oesophagitis—Prednisone—Crohn's disease	0.000126	0.00156	CcSEcCtD
Naproxen—Ecchymosis—Prednisone—Crohn's disease	0.000125	0.00154	CcSEcCtD
Naproxen—Fenoprofen—PTGS2—Crohn's disease	0.000124	0.0425	CrCbGaD
Naproxen—Erythema multiforme—Mesalazine—Crohn's disease	0.000124	0.00153	CcSEcCtD
Naproxen—Pulmonary oedema—Prednisone—Crohn's disease	0.000123	0.00152	CcSEcCtD
Naproxen—Eye disorder—Mesalazine—Crohn's disease	0.000123	0.00151	CcSEcCtD
Naproxen—Tinnitus—Mesalazine—Crohn's disease	0.000122	0.00151	CcSEcCtD
Naproxen—Cardiac disorder—Mesalazine—Crohn's disease	0.000122	0.0015	CcSEcCtD
Naproxen—Sepsis—Prednisone—Crohn's disease	0.00012	0.00148	CcSEcCtD
Naproxen—Angiopathy—Mesalazine—Crohn's disease	0.000119	0.00147	CcSEcCtD
Naproxen—Immune system disorder—Mesalazine—Crohn's disease	0.000118	0.00146	CcSEcCtD
Naproxen—Mediastinal disorder—Mesalazine—Crohn's disease	0.000118	0.00146	CcSEcCtD
Naproxen—Chills—Mesalazine—Crohn's disease	0.000118	0.00145	CcSEcCtD
Naproxen—Diarrhoea—Mercaptopurine—Crohn's disease	0.000117	0.00145	CcSEcCtD
Naproxen—Ill-defined disorder—Azathioprine—Crohn's disease	0.000116	0.00143	CcSEcCtD
Naproxen—Alopecia—Mesalazine—Crohn's disease	0.000116	0.00143	CcSEcCtD
Naproxen—Thrombophlebitis—Prednisone—Crohn's disease	0.000116	0.00143	CcSEcCtD
Naproxen—Anaemia—Azathioprine—Crohn's disease	0.000116	0.00143	CcSEcCtD
Naproxen—Diabetes mellitus—Prednisone—Crohn's disease	0.000115	0.00142	CcSEcCtD
Naproxen—Mental disorder—Mesalazine—Crohn's disease	0.000115	0.00142	CcSEcCtD
Naproxen—Erythema—Mesalazine—Crohn's disease	0.000114	0.00141	CcSEcCtD
Naproxen—Malaise—Azathioprine—Crohn's disease	0.000113	0.00139	CcSEcCtD
Naproxen—Flatulence—Mesalazine—Crohn's disease	0.000112	0.00139	CcSEcCtD
Naproxen—Leukopenia—Azathioprine—Crohn's disease	0.000112	0.00138	CcSEcCtD
Naproxen—Vascular purpura—Prednisone—Crohn's disease	0.000112	0.00138	CcSEcCtD
Naproxen—Tension—Mesalazine—Crohn's disease	0.000112	0.00138	CcSEcCtD
Naproxen—Nervousness—Mesalazine—Crohn's disease	0.000111	0.00137	CcSEcCtD
Naproxen—Fenoprofen—ALB—Crohn's disease	0.000111	0.0379	CrCbGaD
Naproxen—Cardiac failure congestive—Prednisone—Crohn's disease	0.000111	0.00136	CcSEcCtD
Naproxen—Muscle spasms—Mesalazine—Crohn's disease	0.00011	0.00135	CcSEcCtD
Naproxen—Vomiting—Mercaptopurine—Crohn's disease	0.000109	0.00135	CcSEcCtD
Naproxen—Rash—Mercaptopurine—Crohn's disease	0.000108	0.00134	CcSEcCtD
Naproxen—Dermatitis—Mercaptopurine—Crohn's disease	0.000108	0.00133	CcSEcCtD
Naproxen—Vision blurred—Mesalazine—Crohn's disease	0.000108	0.00133	CcSEcCtD
Naproxen—Tremor—Mesalazine—Crohn's disease	0.000107	0.00132	CcSEcCtD
Naproxen—Amnesia—Prednisone—Crohn's disease	0.000107	0.00132	CcSEcCtD
Naproxen—Arthralgia—Azathioprine—Crohn's disease	0.000107	0.00132	CcSEcCtD
Naproxen—Myalgia—Azathioprine—Crohn's disease	0.000107	0.00132	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.000106	0.00131	CcSEcCtD
Naproxen—Ill-defined disorder—Mesalazine—Crohn's disease	0.000106	0.00131	CcSEcCtD
Naproxen—Anaemia—Mesalazine—Crohn's disease	0.000105	0.0013	CcSEcCtD
Naproxen—Discomfort—Azathioprine—Crohn's disease	0.000105	0.0013	CcSEcCtD
Naproxen—Angioedema—Mesalazine—Crohn's disease	0.000104	0.00129	CcSEcCtD
Naproxen—Purpura—Prednisone—Crohn's disease	0.000104	0.00128	CcSEcCtD
Naproxen—Malaise—Mesalazine—Crohn's disease	0.000103	0.00127	CcSEcCtD
Naproxen—Cardiac failure—Prednisone—Crohn's disease	0.000103	0.00127	CcSEcCtD
Naproxen—Vertigo—Mesalazine—Crohn's disease	0.000103	0.00127	CcSEcCtD
Naproxen—Syncope—Mesalazine—Crohn's disease	0.000102	0.00126	CcSEcCtD
Naproxen—Leukopenia—Mesalazine—Crohn's disease	0.000102	0.00126	CcSEcCtD
Naproxen—Nausea—Mercaptopurine—Crohn's disease	0.000102	0.00126	CcSEcCtD
Naproxen—Infection—Azathioprine—Crohn's disease	0.000102	0.00125	CcSEcCtD
Naproxen—Palpitations—Mesalazine—Crohn's disease	0.000101	0.00124	CcSEcCtD
Naproxen—Loss of consciousness—Mesalazine—Crohn's disease	0.0001	0.00124	CcSEcCtD
Naproxen—Osteoarthritis—Prednisone—Crohn's disease	0.0001	0.00124	CcSEcCtD
Naproxen—Gastrointestinal haemorrhage—Prednisone—Crohn's disease	0.0001	0.00124	CcSEcCtD
Naproxen—Thrombocytopenia—Azathioprine—Crohn's disease	0.0001	0.00124	CcSEcCtD
Naproxen—Cough—Mesalazine—Crohn's disease	9.96e-05	0.00123	CcSEcCtD
Naproxen—Skin disorder—Azathioprine—Crohn's disease	9.93e-05	0.00123	CcSEcCtD
Naproxen—Affect lability—Prednisone—Crohn's disease	9.87e-05	0.00122	CcSEcCtD
Naproxen—Hypertension—Mesalazine—Crohn's disease	9.85e-05	0.00122	CcSEcCtD
Naproxen—Chest pain—Mesalazine—Crohn's disease	9.72e-05	0.0012	CcSEcCtD
Naproxen—Myalgia—Mesalazine—Crohn's disease	9.72e-05	0.0012	CcSEcCtD
Naproxen—Arthralgia—Mesalazine—Crohn's disease	9.72e-05	0.0012	CcSEcCtD
Naproxen—Anxiety—Mesalazine—Crohn's disease	9.68e-05	0.00119	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	9.65e-05	0.00119	CcSEcCtD
Naproxen—Discomfort—Mesalazine—Crohn's disease	9.6e-05	0.00118	CcSEcCtD
Naproxen—Hypotension—Azathioprine—Crohn's disease	9.55e-05	0.00118	CcSEcCtD
Naproxen—Dry mouth—Mesalazine—Crohn's disease	9.5e-05	0.00117	CcSEcCtD
Naproxen—Mood swings—Prednisone—Crohn's disease	9.5e-05	0.00117	CcSEcCtD
Naproxen—Confusional state—Mesalazine—Crohn's disease	9.39e-05	0.00116	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Azathioprine—Crohn's disease	9.32e-05	0.00115	CcSEcCtD
Naproxen—Oedema—Mesalazine—Crohn's disease	9.31e-05	0.00115	CcSEcCtD
Naproxen—Anaphylactic shock—Mesalazine—Crohn's disease	9.31e-05	0.00115	CcSEcCtD
Naproxen—Infection—Mesalazine—Crohn's disease	9.25e-05	0.00114	CcSEcCtD
Naproxen—Dry skin—Prednisone—Crohn's disease	9.19e-05	0.00113	CcSEcCtD
Naproxen—Indomethacin—PTGS2—Crohn's disease	9.18e-05	0.0313	CrCbGaD
Naproxen—Shock—Mesalazine—Crohn's disease	9.16e-05	0.00113	CcSEcCtD
Naproxen—Nervous system disorder—Mesalazine—Crohn's disease	9.13e-05	0.00113	CcSEcCtD
Naproxen—Hypokalaemia—Prednisone—Crohn's disease	9.13e-05	0.00113	CcSEcCtD
Naproxen—Thrombocytopenia—Mesalazine—Crohn's disease	9.12e-05	0.00113	CcSEcCtD
Naproxen—Tachycardia—Mesalazine—Crohn's disease	9.09e-05	0.00112	CcSEcCtD
Naproxen—Skin disorder—Mesalazine—Crohn's disease	9.05e-05	0.00112	CcSEcCtD
Naproxen—Hyperhidrosis—Mesalazine—Crohn's disease	9e-05	0.00111	CcSEcCtD
Naproxen—Anorexia—Mesalazine—Crohn's disease	8.88e-05	0.0011	CcSEcCtD
Naproxen—Muscular weakness—Prednisone—Crohn's disease	8.84e-05	0.00109	CcSEcCtD
Naproxen—Gastrointestinal disorder—Azathioprine—Crohn's disease	8.83e-05	0.00109	CcSEcCtD
Naproxen—Abdominal distension—Prednisone—Crohn's disease	8.72e-05	0.00108	CcSEcCtD
Naproxen—Hypotension—Mesalazine—Crohn's disease	8.7e-05	0.00107	CcSEcCtD
Naproxen—Pancreatitis—Prednisone—Crohn's disease	8.5e-05	0.00105	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Mesalazine—Crohn's disease	8.49e-05	0.00105	CcSEcCtD
Naproxen—Feeling abnormal—Azathioprine—Crohn's disease	8.43e-05	0.00104	CcSEcCtD
Naproxen—Insomnia—Mesalazine—Crohn's disease	8.42e-05	0.00104	CcSEcCtD
Naproxen—Paraesthesia—Mesalazine—Crohn's disease	8.36e-05	0.00103	CcSEcCtD
Naproxen—Gastrointestinal pain—Azathioprine—Crohn's disease	8.36e-05	0.00103	CcSEcCtD
Naproxen—Dyspnoea—Mesalazine—Crohn's disease	8.3e-05	0.00102	CcSEcCtD
Naproxen—Somnolence—Mesalazine—Crohn's disease	8.28e-05	0.00102	CcSEcCtD
Naproxen—Dyspepsia—Mesalazine—Crohn's disease	8.2e-05	0.00101	CcSEcCtD
Naproxen—Indomethacin—ALB—Crohn's disease	8.17e-05	0.0279	CrCbGaD
Naproxen—Flurbiprofen—PTGS2—Crohn's disease	8.11e-05	0.0277	CrCbGaD
Naproxen—Decreased appetite—Mesalazine—Crohn's disease	8.1e-05	0.000999	CcSEcCtD
Naproxen—Abdominal pain—Azathioprine—Crohn's disease	8.08e-05	0.000997	CcSEcCtD
Naproxen—Body temperature increased—Azathioprine—Crohn's disease	8.08e-05	0.000997	CcSEcCtD
Naproxen—Gastrointestinal disorder—Mesalazine—Crohn's disease	8.04e-05	0.000992	CcSEcCtD
Naproxen—Fatigue—Mesalazine—Crohn's disease	8.03e-05	0.000991	CcSEcCtD
Naproxen—Pain—Mesalazine—Crohn's disease	7.96e-05	0.000983	CcSEcCtD
Naproxen—Constipation—Mesalazine—Crohn's disease	7.96e-05	0.000983	CcSEcCtD
Naproxen—Weight decreased—Prednisone—Crohn's disease	7.84e-05	0.000967	CcSEcCtD
Naproxen—Hyperglycaemia—Prednisone—Crohn's disease	7.82e-05	0.000965	CcSEcCtD
Naproxen—Depression—Prednisone—Crohn's disease	7.7e-05	0.000951	CcSEcCtD
Naproxen—Feeling abnormal—Mesalazine—Crohn's disease	7.68e-05	0.000947	CcSEcCtD
Naproxen—Acute coronary syndrome—Prednisone—Crohn's disease	7.62e-05	0.00094	CcSEcCtD
Naproxen—Gastrointestinal pain—Mesalazine—Crohn's disease	7.62e-05	0.00094	CcSEcCtD
Naproxen—Neuropathy peripheral—Prednisone—Crohn's disease	7.57e-05	0.000935	CcSEcCtD
Naproxen—Myocardial infarction—Prednisone—Crohn's disease	7.57e-05	0.000935	CcSEcCtD
Naproxen—Hypersensitivity—Azathioprine—Crohn's disease	7.53e-05	0.00093	CcSEcCtD
Naproxen—Urticaria—Mesalazine—Crohn's disease	7.4e-05	0.000913	CcSEcCtD
Naproxen—Abdominal pain—Mesalazine—Crohn's disease	7.36e-05	0.000908	CcSEcCtD
Naproxen—Body temperature increased—Mesalazine—Crohn's disease	7.36e-05	0.000908	CcSEcCtD
Naproxen—Ketoprofen—PTGS2—Crohn's disease	7.34e-05	0.0251	CrCbGaD
Naproxen—Flurbiprofen—ALB—Crohn's disease	7.23e-05	0.0247	CrCbGaD
Naproxen—Ibuprofen—PTGS2—Crohn's disease	7.23e-05	0.0247	CrCbGaD
Naproxen—Diarrhoea—Azathioprine—Crohn's disease	7e-05	0.000863	CcSEcCtD
Naproxen—Haemoglobin—Prednisone—Crohn's disease	6.97e-05	0.00086	CcSEcCtD
Naproxen—Haemorrhage—Prednisone—Crohn's disease	6.94e-05	0.000856	CcSEcCtD
Naproxen—Hallucination—Prednisone—Crohn's disease	6.9e-05	0.000852	CcSEcCtD
Naproxen—Hypersensitivity—Mesalazine—Crohn's disease	6.86e-05	0.000847	CcSEcCtD
Naproxen—Connective tissue disorder—Prednisone—Crohn's disease	6.82e-05	0.000841	CcSEcCtD
Naproxen—Dizziness—Azathioprine—Crohn's disease	6.76e-05	0.000834	CcSEcCtD
Naproxen—Asthenia—Mesalazine—Crohn's disease	6.68e-05	0.000825	CcSEcCtD
Naproxen—Pruritus—Mesalazine—Crohn's disease	6.59e-05	0.000813	CcSEcCtD
Naproxen—Ketoprofen—ALB—Crohn's disease	6.54e-05	0.0223	CrCbGaD
Naproxen—Vomiting—Azathioprine—Crohn's disease	6.5e-05	0.000802	CcSEcCtD
Naproxen—Eye disorder—Prednisone—Crohn's disease	6.48e-05	0.0008	CcSEcCtD
Naproxen—Rash—Azathioprine—Crohn's disease	6.45e-05	0.000796	CcSEcCtD
Naproxen—Dermatitis—Azathioprine—Crohn's disease	6.44e-05	0.000795	CcSEcCtD
Naproxen—Ibuprofen—ALB—Crohn's disease	6.44e-05	0.022	CrCbGaD
Naproxen—Headache—Azathioprine—Crohn's disease	6.41e-05	0.00079	CcSEcCtD
Naproxen—Diarrhoea—Mesalazine—Crohn's disease	6.37e-05	0.000786	CcSEcCtD
Naproxen—Angiopathy—Prednisone—Crohn's disease	6.29e-05	0.000777	CcSEcCtD
Naproxen—Immune system disorder—Prednisone—Crohn's disease	6.27e-05	0.000773	CcSEcCtD
Naproxen—Arrhythmia—Prednisone—Crohn's disease	6.2e-05	0.000765	CcSEcCtD
Naproxen—Dizziness—Mesalazine—Crohn's disease	6.16e-05	0.00076	CcSEcCtD
Naproxen—Alopecia—Prednisone—Crohn's disease	6.13e-05	0.000756	CcSEcCtD
Naproxen—Mental disorder—Prednisone—Crohn's disease	6.08e-05	0.00075	CcSEcCtD
Naproxen—Nausea—Azathioprine—Crohn's disease	6.07e-05	0.000749	CcSEcCtD
Naproxen—Malnutrition—Prednisone—Crohn's disease	6.04e-05	0.000745	CcSEcCtD
Naproxen—Erythema—Prednisone—Crohn's disease	6.04e-05	0.000745	CcSEcCtD
Naproxen—Vomiting—Mesalazine—Crohn's disease	5.92e-05	0.000731	CcSEcCtD
Naproxen—Rash—Mesalazine—Crohn's disease	5.87e-05	0.000725	CcSEcCtD
Naproxen—Dermatitis—Mesalazine—Crohn's disease	5.87e-05	0.000724	CcSEcCtD
Naproxen—Headache—Mesalazine—Crohn's disease	5.84e-05	0.00072	CcSEcCtD
Naproxen—Vision blurred—Prednisone—Crohn's disease	5.69e-05	0.000702	CcSEcCtD
Naproxen—Ill-defined disorder—Prednisone—Crohn's disease	5.6e-05	0.000691	CcSEcCtD
Naproxen—Anaemia—Prednisone—Crohn's disease	5.58e-05	0.000689	CcSEcCtD
Naproxen—Nausea—Mesalazine—Crohn's disease	5.53e-05	0.000683	CcSEcCtD
Naproxen—Angioedema—Prednisone—Crohn's disease	5.52e-05	0.000681	CcSEcCtD
Naproxen—Malaise—Prednisone—Crohn's disease	5.45e-05	0.000672	CcSEcCtD
Naproxen—Vertigo—Prednisone—Crohn's disease	5.43e-05	0.000669	CcSEcCtD
Naproxen—Syncope—Prednisone—Crohn's disease	5.41e-05	0.000668	CcSEcCtD
Naproxen—Loss of consciousness—Prednisone—Crohn's disease	5.31e-05	0.000655	CcSEcCtD
Naproxen—Convulsion—Prednisone—Crohn's disease	5.23e-05	0.000646	CcSEcCtD
Naproxen—Hypertension—Prednisone—Crohn's disease	5.21e-05	0.000643	CcSEcCtD
Naproxen—Arthralgia—Prednisone—Crohn's disease	5.14e-05	0.000634	CcSEcCtD
Naproxen—Myalgia—Prednisone—Crohn's disease	5.14e-05	0.000634	CcSEcCtD
Naproxen—Anxiety—Prednisone—Crohn's disease	5.12e-05	0.000632	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	5.11e-05	0.00063	CcSEcCtD
Naproxen—Discomfort—Prednisone—Crohn's disease	5.08e-05	0.000627	CcSEcCtD
Naproxen—Anaphylactic shock—Prednisone—Crohn's disease	4.93e-05	0.000608	CcSEcCtD
Naproxen—Oedema—Prednisone—Crohn's disease	4.93e-05	0.000608	CcSEcCtD
Naproxen—Infection—Prednisone—Crohn's disease	4.9e-05	0.000604	CcSEcCtD
Naproxen—Shock—Prednisone—Crohn's disease	4.85e-05	0.000598	CcSEcCtD
Naproxen—Nervous system disorder—Prednisone—Crohn's disease	4.83e-05	0.000596	CcSEcCtD
Naproxen—Tachycardia—Prednisone—Crohn's disease	4.81e-05	0.000593	CcSEcCtD
Naproxen—Skin disorder—Prednisone—Crohn's disease	4.79e-05	0.000591	CcSEcCtD
Naproxen—Hyperhidrosis—Prednisone—Crohn's disease	4.76e-05	0.000588	CcSEcCtD
Naproxen—Anorexia—Prednisone—Crohn's disease	4.7e-05	0.00058	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Prednisone—Crohn's disease	4.49e-05	0.000554	CcSEcCtD
Naproxen—Insomnia—Prednisone—Crohn's disease	4.46e-05	0.00055	CcSEcCtD
Naproxen—Paraesthesia—Prednisone—Crohn's disease	4.43e-05	0.000546	CcSEcCtD
Naproxen—Dyspepsia—Prednisone—Crohn's disease	4.34e-05	0.000535	CcSEcCtD
Naproxen—Decreased appetite—Prednisone—Crohn's disease	4.28e-05	0.000529	CcSEcCtD
Naproxen—Fatigue—Prednisone—Crohn's disease	4.25e-05	0.000524	CcSEcCtD
Naproxen—Constipation—Prednisone—Crohn's disease	4.21e-05	0.00052	CcSEcCtD
Naproxen—ALB—gall bladder—Crohn's disease	4.11e-05	0.109	CbGeAlD
Naproxen—Feeling abnormal—Prednisone—Crohn's disease	4.06e-05	0.000501	CcSEcCtD
Naproxen—Gastrointestinal pain—Prednisone—Crohn's disease	4.03e-05	0.000497	CcSEcCtD
Naproxen—Urticaria—Prednisone—Crohn's disease	3.91e-05	0.000483	CcSEcCtD
Naproxen—Body temperature increased—Prednisone—Crohn's disease	3.9e-05	0.000481	CcSEcCtD
Naproxen—Abdominal pain—Prednisone—Crohn's disease	3.9e-05	0.000481	CcSEcCtD
Naproxen—ALB—Vitamin B12 Metabolism—CRP—Crohn's disease	3.7e-05	0.00297	CbGpPWpGaD
Naproxen—PTGS2—Overview of nanoparticle effects—IL6—Crohn's disease	3.68e-05	0.00295	CbGpPWpGaD
Naproxen—Hypersensitivity—Prednisone—Crohn's disease	3.63e-05	0.000448	CcSEcCtD
Naproxen—AKR1C3—Disease—RSPO3—Crohn's disease	3.59e-05	0.00288	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	3.57e-05	0.00287	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	3.57e-05	0.00287	CbGpPWpGaD
Naproxen—Asthenia—Prednisone—Crohn's disease	3.54e-05	0.000436	CcSEcCtD
Naproxen—Pruritus—Prednisone—Crohn's disease	3.49e-05	0.00043	CcSEcCtD
Naproxen—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—Crohn's disease	3.47e-05	0.00279	CbGpPWpGaD
Naproxen—CYP2C8—Metapathway biotransformation—GPX4—Crohn's disease	3.46e-05	0.00278	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PLA2G4F—Crohn's disease	3.44e-05	0.00276	CbGpPWpGaD
Naproxen—ALB—SLC-mediated transmembrane transport—SLC22A4—Crohn's disease	3.43e-05	0.00276	CbGpPWpGaD
Naproxen—ALB—SLC-mediated transmembrane transport—SLC22A5—Crohn's disease	3.43e-05	0.00276	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—ICAM1—Crohn's disease	3.42e-05	0.00275	CbGpPWpGaD
Naproxen—AKR1C3—Disease—SEL1L—Crohn's disease	3.4e-05	0.00273	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—ICAM1—Crohn's disease	3.4e-05	0.00273	CbGpPWpGaD
Naproxen—Diarrhoea—Prednisone—Crohn's disease	3.37e-05	0.000416	CcSEcCtD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	3.36e-05	0.0027	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	3.36e-05	0.0027	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	3.36e-05	0.0027	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—ACKR2—Crohn's disease	3.31e-05	0.00266	CbGpPWpGaD
Naproxen—AKR1C3—smooth muscle tissue—Crohn's disease	3.3e-05	0.0877	CbGeAlD
Naproxen—Dizziness—Prednisone—Crohn's disease	3.26e-05	0.000402	CcSEcCtD
Naproxen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—Crohn's disease	3.25e-05	0.00261	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MLN—Crohn's disease	3.14e-05	0.00252	CbGpPWpGaD
Naproxen—Vomiting—Prednisone—Crohn's disease	3.13e-05	0.000387	CcSEcCtD
Naproxen—Rash—Prednisone—Crohn's disease	3.11e-05	0.000383	CcSEcCtD
Naproxen—Dermatitis—Prednisone—Crohn's disease	3.1e-05	0.000383	CcSEcCtD
Naproxen—Headache—Prednisone—Crohn's disease	3.09e-05	0.000381	CcSEcCtD
Naproxen—AKR1C3—Disease—LTF—Crohn's disease	3.05e-05	0.00245	CbGpPWpGaD
Naproxen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—Crohn's disease	3.02e-05	0.00243	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—CRP—Crohn's disease	3.01e-05	0.00242	CbGpPWpGaD
Naproxen—AKR1C3—mammalian vulva—Crohn's disease	2.97e-05	0.0789	CbGeAlD
Naproxen—PTGS2—Selenium Micronutrient Network—CRP—Crohn's disease	2.95e-05	0.00237	CbGpPWpGaD
Naproxen—Nausea—Prednisone—Crohn's disease	2.93e-05	0.000361	CcSEcCtD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	2.93e-05	0.00235	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—MTMR3—Crohn's disease	2.92e-05	0.00235	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—F5—Crohn's disease	2.89e-05	0.00232	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TAGAP—Crohn's disease	2.87e-05	0.00231	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	2.86e-05	0.00229	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—ALB—Crohn's disease	2.85e-05	0.00229	CbGpPWpGaD
Naproxen—UGT2B7—digestive system—Crohn's disease	2.83e-05	0.0751	CbGeAlD
Naproxen—CYP2C9—Metapathway biotransformation—GPX4—Crohn's disease	2.81e-05	0.00226	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—ICAM1—Crohn's disease	2.76e-05	0.00222	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	2.74e-05	0.0022	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—ICAM1—Crohn's disease	2.71e-05	0.00218	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	2.67e-05	0.00214	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—IFNG—Crohn's disease	2.6e-05	0.00209	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—IFNG—Crohn's disease	2.59e-05	0.00208	CbGpPWpGaD
Naproxen—CYP2C8—Arachidonic acid metabolism—PTGS2—Crohn's disease	2.53e-05	0.00203	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—GCKR—Crohn's disease	2.52e-05	0.00202	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—RSPO3—Crohn's disease	2.51e-05	0.00202	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—PTGS2—Crohn's disease	2.49e-05	0.002	CbGpPWpGaD
Naproxen—AKR1C3—Disease—GCKR—Crohn's disease	2.46e-05	0.00198	CbGpPWpGaD
Naproxen—ALB—SLC-mediated transmembrane transport—GCKR—Crohn's disease	2.42e-05	0.00194	CbGpPWpGaD
Naproxen—CYP1A2—Metapathway biotransformation—GPX4—Crohn's disease	2.4e-05	0.00193	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—IL3—Crohn's disease	2.4e-05	0.00193	CbGpPWpGaD
Naproxen—UGT1A1—digestive system—Crohn's disease	2.4e-05	0.0638	CbGeAlD
Naproxen—ALB—Selenium Micronutrient Network—CRP—Crohn's disease	2.39e-05	0.00192	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SEL1L—Crohn's disease	2.38e-05	0.00191	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—GCKR—Crohn's disease	2.36e-05	0.0019	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—IL1B—Crohn's disease	2.32e-05	0.00186	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—IL1B—Crohn's disease	2.31e-05	0.00185	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—FADS1—Crohn's disease	2.28e-05	0.00183	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	2.27e-05	0.00182	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—ALB—Crohn's disease	2.26e-05	0.00182	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PLA2G4F—Crohn's disease	2.26e-05	0.00181	CbGpPWpGaD
Naproxen—PTGS2—Aryl Hydrocarbon Receptor—TNF—Crohn's disease	2.25e-05	0.0018	CbGpPWpGaD
Naproxen—PTGS2—gall bladder—Crohn's disease	2.24e-05	0.0595	CbGeAlD
Naproxen—PTGS2—Spinal Cord Injury—TLR4—Crohn's disease	2.24e-05	0.0018	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	2.23e-05	0.00179	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	2.22e-05	0.00179	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—ICAM1—Crohn's disease	2.2e-05	0.00176	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCR9—Crohn's disease	2.18e-05	0.00175	CbGpPWpGaD
Naproxen—AKR1C3—Disease—SLC11A1—Crohn's disease	2.17e-05	0.00175	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	2.17e-05	0.00174	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	2.16e-05	0.00173	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—ICAM1—Crohn's disease	2.15e-05	0.00172	CbGpPWpGaD
Naproxen—ALB—SLC-mediated transmembrane transport—SLC11A1—Crohn's disease	2.14e-05	0.00172	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—GPX4—Crohn's disease	2.13e-05	0.00171	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—IFNG—Crohn's disease	2.1e-05	0.00169	CbGpPWpGaD
Naproxen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—Crohn's disease	2.1e-05	0.00169	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	2.09e-05	0.00168	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	2.08e-05	0.00167	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—CD4—Crohn's disease	2.07e-05	0.00166	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—IFNG—Crohn's disease	2.07e-05	0.00166	CbGpPWpGaD
Naproxen—CYP2C9—Arachidonic acid metabolism—PTGS2—Crohn's disease	2.06e-05	0.00166	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—GCKR—Crohn's disease	2.06e-05	0.00165	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—GPR65—Crohn's disease	2.02e-05	0.00163	CbGpPWpGaD
Naproxen—PTGS2—mouth—Crohn's disease	1.99e-05	0.0529	CbGeAlD
Naproxen—SLCO1A2—Metabolism—PLA2G4F—Crohn's disease	1.97e-05	0.00158	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Crohn's disease	1.96e-05	0.00158	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—MTMR3—Crohn's disease	1.92e-05	0.00154	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—Crohn's disease	1.88e-05	0.00151	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—IL1B—Crohn's disease	1.88e-05	0.00151	CbGpPWpGaD
Naproxen—AKR1C3—Disease—RBX1—Crohn's disease	1.86e-05	0.0015	CbGpPWpGaD
Naproxen—AKR1C3—Disease—HSPA1B—Crohn's disease	1.86e-05	0.0015	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	1.85e-05	0.00148	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—IL1B—Crohn's disease	1.84e-05	0.00148	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PLA2G4F—Crohn's disease	1.84e-05	0.00147	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	1.83e-05	0.00147	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	1.77e-05	0.00142	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	1.77e-05	0.00142	CbGpPWpGaD
Naproxen—CYP1A2—Arachidonic acid metabolism—PTGS2—Crohn's disease	1.76e-05	0.00142	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Crohn's disease	1.75e-05	0.00141	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	1.74e-05	0.0014	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	1.74e-05	0.0014	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—IL3—Crohn's disease	1.73e-05	0.00139	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—TNF—Crohn's disease	1.68e-05	0.00135	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—RASGRP1—Crohn's disease	1.67e-05	0.00134	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—TNF—Crohn's disease	1.67e-05	0.00134	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—MTMR3—Crohn's disease	1.67e-05	0.00134	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—IFNG—Crohn's disease	1.67e-05	0.00134	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	1.65e-05	0.00133	CbGpPWpGaD
Naproxen—AKR1C3—Disease—UBE2D1—Crohn's disease	1.63e-05	0.00131	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—IFNG—Crohn's disease	1.63e-05	0.00131	CbGpPWpGaD
Naproxen—SLCO1A2—digestive system—Crohn's disease	1.63e-05	0.0432	CbGeAlD
Naproxen—ALB—Selenium Micronutrient Network—PTGS2—Crohn's disease	1.6e-05	0.00129	CbGpPWpGaD
Naproxen—SLCO1A2—SLC-mediated transmembrane transport—ALB—Crohn's disease	1.58e-05	0.00127	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—MTMR3—Crohn's disease	1.56e-05	0.00125	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—CXCL8—Crohn's disease	1.52e-05	0.00122	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	1.51e-05	0.00121	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	1.5e-05	0.00121	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PLA2G4F—Crohn's disease	1.5e-05	0.0012	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—FADS1—Crohn's disease	1.5e-05	0.0012	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—IL1B—Crohn's disease	1.49e-05	0.0012	CbGpPWpGaD
Naproxen—AKR1C3—lymph node—Crohn's disease	1.49e-05	0.0395	CbGeAlD
Naproxen—ALB—Hemostasis—F5—Crohn's disease	1.49e-05	0.0012	CbGpPWpGaD
Naproxen—SLC22A6—SLC-mediated transmembrane transport—ALB—Crohn's disease	1.48e-05	0.00119	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.47e-05	0.00118	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—IL1B—Crohn's disease	1.46e-05	0.00117	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCR6—Crohn's disease	1.44e-05	0.00116	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	1.44e-05	0.00115	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	1.43e-05	0.00115	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GPX4—Crohn's disease	1.4e-05	0.00113	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—TNF—Crohn's disease	1.36e-05	0.00109	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—IL6—Crohn's disease	1.36e-05	0.00109	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GCKR—Crohn's disease	1.35e-05	0.00109	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—IL6—Crohn's disease	1.35e-05	0.00108	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	1.35e-05	0.00108	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	1.34e-05	0.00108	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—TNF—Crohn's disease	1.34e-05	0.00107	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—RBX1—Crohn's disease	1.3e-05	0.00105	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—FADS1—Crohn's disease	1.3e-05	0.00105	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.29e-05	0.00103	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	1.28e-05	0.00103	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—MTMR3—Crohn's disease	1.27e-05	0.00102	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Crohn's disease	1.27e-05	0.00102	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Crohn's disease	1.27e-05	0.00102	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PTGER4—Crohn's disease	1.27e-05	0.00102	CbGpPWpGaD
Naproxen—PTGS2—Disease—RSPO3—Crohn's disease	1.24e-05	0.000996	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—GCKR—Crohn's disease	1.23e-05	0.000987	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GPX4—Crohn's disease	1.22e-05	0.00098	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—FADS1—Crohn's disease	1.22e-05	0.000977	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—IL2RA—Crohn's disease	1.21e-05	0.000974	CbGpPWpGaD
Naproxen—PTGS1—epithelium—Crohn's disease	1.21e-05	0.0322	CbGeAlD
Naproxen—PTGS2—Metabolism—PLA2G4F—Crohn's disease	1.19e-05	0.000954	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GCKR—Crohn's disease	1.18e-05	0.000947	CbGpPWpGaD
Naproxen—PTGS2—Disease—SEL1L—Crohn's disease	1.18e-05	0.000944	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	1.17e-05	0.00094	CbGpPWpGaD
Naproxen—AKR1C3—Disease—SMAD3—Crohn's disease	1.17e-05	0.000939	CbGpPWpGaD
Naproxen—PTGS1—smooth muscle tissue—Crohn's disease	1.17e-05	0.031	CbGeAlD
Naproxen—PTGS2—epithelium—Crohn's disease	1.16e-05	0.0308	CbGeAlD
Naproxen—PTGS1—skin of body—Crohn's disease	1.15e-05	0.0306	CbGeAlD
Naproxen—AKR1C3—Signaling Pathways—UBE2D1—Crohn's disease	1.14e-05	0.000919	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GPX4—Crohn's disease	1.14e-05	0.000915	CbGpPWpGaD
Naproxen—PTGS2—smooth muscle tissue—Crohn's disease	1.12e-05	0.0296	CbGeAlD
Naproxen—AKR1C3—Signaling Pathways—RIPK2—Crohn's disease	1.11e-05	0.000891	CbGpPWpGaD
Naproxen—PTGS2—skin of body—Crohn's disease	1.1e-05	0.0293	CbGeAlD
Naproxen—UGT1A1—Metabolism—GCKR—Crohn's disease	1.1e-05	0.000883	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—IL6—Crohn's disease	1.1e-05	0.000883	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	1.1e-05	0.00088	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	1.09e-05	0.000873	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL3—Crohn's disease	1.08e-05	0.000869	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—TNF—Crohn's disease	1.08e-05	0.000869	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—IL6—Crohn's disease	1.08e-05	0.000867	CbGpPWpGaD
Naproxen—CYP1A2—digestive system—Crohn's disease	1.06e-05	0.0283	CbGeAlD
Naproxen—PTGS2—Spinal Cord Injury—TNF—Crohn's disease	1.06e-05	0.000849	CbGpPWpGaD
Naproxen—PTGS2—Disease—LTF—Crohn's disease	1.05e-05	0.000847	CbGpPWpGaD
Naproxen—PTGS1—mammalian vulva—Crohn's disease	1.05e-05	0.0279	CbGeAlD
Naproxen—AKR1C3—Signaling Pathways—RASGRP1—Crohn's disease	1.05e-05	0.000841	CbGpPWpGaD
Naproxen—CYP2C9—digestive system—Crohn's disease	1.01e-05	0.0268	CbGeAlD
Naproxen—PTGS2—Metabolism—MTMR3—Crohn's disease	1.01e-05	0.000811	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	1e-05	0.000803	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—FADS1—Crohn's disease	9.91e-06	0.000796	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PLA2G4F—Crohn's disease	9.66e-06	0.000776	CbGpPWpGaD
Naproxen—ALB—Metabolism—PLA2G4F—Crohn's disease	9.61e-06	0.000772	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SOCS1—Crohn's disease	9.48e-06	0.000762	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	9.36e-06	0.000752	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GPX4—Crohn's disease	9.28e-06	0.000746	CbGpPWpGaD
Naproxen—ALB—lymph node—Crohn's disease	9.24e-06	0.0245	CbGeAlD
Naproxen—PTGS1—digestive system—Crohn's disease	9.22e-06	0.0245	CbGeAlD
Naproxen—ALB—Hemostasis—ITGA4—Crohn's disease	9.15e-06	0.000735	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GCKR—Crohn's disease	8.96e-06	0.00072	CbGpPWpGaD
Naproxen—PTGS2—lymphoid tissue—Crohn's disease	8.92e-06	0.0237	CbGeAlD
Naproxen—ALB—Hemostasis—IL3—Crohn's disease	8.92e-06	0.000717	CbGpPWpGaD
Naproxen—PTGS2—digestive system—Crohn's disease	8.81e-06	0.0234	CbGeAlD
Naproxen—ALB—Selenium Micronutrient Network—IL6—Crohn's disease	8.73e-06	0.000701	CbGpPWpGaD
Naproxen—ALB—Hemostasis—RASGRP1—Crohn's disease	8.63e-06	0.000693	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—IL6—Crohn's disease	8.53e-06	0.000685	CbGpPWpGaD
Naproxen—PTGS2—Disease—GCKR—Crohn's disease	8.5e-06	0.000683	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	8.42e-06	0.000676	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—MTMR3—Crohn's disease	8.22e-06	0.00066	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SMAD3—Crohn's disease	8.19e-06	0.000658	CbGpPWpGaD
Naproxen—ALB—Metabolism—MTMR3—Crohn's disease	8.17e-06	0.000656	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	8.15e-06	0.000655	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—ALB—Crohn's disease	8.01e-06	0.000643	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—FADS1—Crohn's disease	7.87e-06	0.000632	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PLA2G4F—Crohn's disease	7.87e-06	0.000632	CbGpPWpGaD
Naproxen—AKR1C3—Disease—TYK2—Crohn's disease	7.63e-06	0.000613	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL2RA—Crohn's disease	7.58e-06	0.000609	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—ALB—Crohn's disease	7.52e-06	0.000605	CbGpPWpGaD
Naproxen—PTGS2—Disease—SLC11A1—Crohn's disease	7.51e-06	0.000603	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GPX4—Crohn's disease	7.37e-06	0.000592	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	7.37e-06	0.000592	CbGpPWpGaD
Naproxen—AKR1C3—Disease—JAK2—Crohn's disease	7.27e-06	0.000584	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	7.19e-06	0.000578	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GCKR—Crohn's disease	7.12e-06	0.000572	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CD4—Crohn's disease	6.9e-06	0.000554	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PTGS2—Crohn's disease	6.85e-06	0.00055	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PLA2G4F—Crohn's disease	6.72e-06	0.00054	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—MTMR3—Crohn's disease	6.69e-06	0.000537	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—ALB—Crohn's disease	6.55e-06	0.000526	CbGpPWpGaD
Naproxen—PTGS2—Disease—RBX1—Crohn's disease	6.44e-06	0.000517	CbGpPWpGaD
Naproxen—PTGS2—Disease—HSPA1B—Crohn's disease	6.44e-06	0.000517	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	6.41e-06	0.000515	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—FADS1—Crohn's disease	6.4e-06	0.000514	CbGpPWpGaD
Naproxen—ALB—Metabolism—FADS1—Crohn's disease	6.37e-06	0.000511	CbGpPWpGaD
Naproxen—ALB—Hemostasis—IL2RA—Crohn's disease	6.25e-06	0.000502	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GPX4—Crohn's disease	5.99e-06	0.000482	CbGpPWpGaD
Naproxen—ALB—Metabolism—GPX4—Crohn's disease	5.96e-06	0.000479	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GCKR—Crohn's disease	5.79e-06	0.000465	CbGpPWpGaD
Naproxen—ALB—Metabolism—GCKR—Crohn's disease	5.76e-06	0.000462	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTGS2—Crohn's disease	5.73e-06	0.000461	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—MTMR3—Crohn's disease	5.71e-06	0.000459	CbGpPWpGaD
Naproxen—PTGS2—Disease—UBE2D1—Crohn's disease	5.65e-06	0.000454	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	5.6e-06	0.00045	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TYK2—Crohn's disease	5.34e-06	0.000429	CbGpPWpGaD
Naproxen—AKR1C3—Disease—STAT3—Crohn's disease	5.34e-06	0.000429	CbGpPWpGaD
Naproxen—PTGS1—lymph node—Crohn's disease	5.27e-06	0.014	CbGeAlD
Naproxen—CYP2C9—Metabolism—FADS1—Crohn's disease	5.21e-06	0.000419	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—JAK2—Crohn's disease	5.09e-06	0.000409	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	5.08e-06	0.000408	CbGpPWpGaD
Naproxen—PTGS2—lymph node—Crohn's disease	5.04e-06	0.0134	CbGeAlD
Naproxen—CYP2C9—Metabolism—GPX4—Crohn's disease	4.88e-06	0.000392	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GCKR—Crohn's disease	4.71e-06	0.000379	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CXCL8—Crohn's disease	4.65e-06	0.000374	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—FADS1—Crohn's disease	4.45e-06	0.000358	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—ALB—Crohn's disease	4.31e-06	0.000346	CbGpPWpGaD
Naproxen—ALB—Hemostasis—JAK2—Crohn's disease	4.2e-06	0.000337	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GPX4—Crohn's disease	4.17e-06	0.000335	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	4.14e-06	0.000332	CbGpPWpGaD
Naproxen—PTGS2—Disease—SMAD3—Crohn's disease	4.04e-06	0.000324	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GCKR—Crohn's disease	4.03e-06	0.000323	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTGS2—Crohn's disease	3.77e-06	0.000303	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—ALB—Crohn's disease	3.75e-06	0.000301	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—STAT3—Crohn's disease	3.74e-06	0.0003	CbGpPWpGaD
Naproxen—AKR1C3—Disease—IL6—Crohn's disease	3.73e-06	0.0003	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	3.62e-06	0.000291	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	3.6e-06	0.000289	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—ALB—Crohn's disease	3.5e-06	0.000281	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	3.37e-06	0.000271	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTGS2—Crohn's disease	3.28e-06	0.000264	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTGS2—Crohn's disease	3.06e-06	0.000246	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	2.95e-06	0.000237	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	2.88e-06	0.000231	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ALB—Crohn's disease	2.85e-06	0.000229	CbGpPWpGaD
Naproxen—PTGS2—Disease—TYK2—Crohn's disease	2.63e-06	0.000212	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL6—Crohn's disease	2.61e-06	0.00021	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	2.52e-06	0.000202	CbGpPWpGaD
Naproxen—PTGS2—Disease—JAK2—Crohn's disease	2.51e-06	0.000202	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTGS2—Crohn's disease	2.5e-06	0.0002	CbGpPWpGaD
Naproxen—PTGS2—Disease—CD4—Crohn's disease	2.38e-06	0.000191	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ALB—Crohn's disease	2.26e-06	0.000182	CbGpPWpGaD
Naproxen—PTGS2—Disease—STAT3—Crohn's disease	1.85e-06	0.000148	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ALB—Crohn's disease	1.84e-06	0.000148	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTGS2—Crohn's disease	1.61e-06	0.00013	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTGS2—Crohn's disease	1.6e-06	0.000129	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ALB—Crohn's disease	1.5e-06	0.00012	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGS2—Crohn's disease	1.31e-06	0.000105	CbGpPWpGaD
Naproxen—PTGS2—Disease—IL6—Crohn's disease	1.29e-06	0.000104	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALB—Crohn's disease	1.28e-06	0.000103	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGS2—Crohn's disease	1.12e-06	9.01e-05	CbGpPWpGaD
